The clinical application of traditional Chinese medicine NRICM101 in hospitalized patients with COVID-19

Wen Kuei Chang, Chieh Jen Wang*, Tung Hu Tsai, Fang Ju Sun, Chao Hsien Chen, Kuan Chih Kuo, Hsin Pei Chung, Yen Hsiang Tang, Yen Ting Chen, Kuo Lun Wu, Jou Chun Wu, Chang Yi Lin, Hai Bo Zhang

*此作品的通信作者

研究成果: Article同行評審

摘要

Background: The aim of this study was to assess the efficacy and safety of NRICM101 in hospitalized patients with COVID-19. Research design and methods: We conducted a retrospective study from 20 April 2021 to 8 July 2021, and evaluated the safety and outcomes (mortality, hospital stay, mechanical ventilation, oxygen support, diarrhea, serum potassium) in COVID-19 patients. Propensity score matching at a 1:2 ratio was performed to reduce confounding factors. Results: A total of 201 patients were analyzed. The experimental group (n = 67) received NRICM101 and standard care, while the control group (n = 134) received standard care alone. No significant differences were observed in mortality (10.4% vs. 14.2%), intubation (13.8% vs. 11%), time to intubation (10 vs. 11 days), mechanical ventilation days (0 vs. 9 days), or oxygen support duration (6 vs. 5 days). However, the experimental group had a shorter length of hospitalization (odds ratio = 0.12, p = 0.043) and fewer mechanical ventilation days (odds ratio = 0.068, p = 0.008) in initially severe cases, along with an increased diarrhea risk (p = 0.035). Conclusion: NRICM101 did not reduce in-hospital mortality. However, it shortened the length of hospitalization and reduced mechanical ventilation days in initially severe cases. Further investigation is needed.

原文English
期刊Expert Review of Anti-Infective Therapy
DOIs
出版狀態Accepted/In press - 2024

指紋

深入研究「The clinical application of traditional Chinese medicine NRICM101 in hospitalized patients with COVID-19」主題。共同形成了獨特的指紋。

引用此